Boardroom Alpha
10-K primary document
RCUS · Annual Report (Form 10-K) · Filed February 25, 2026

Arcus Biosciences Inc10-K exhibit

a2025q4exhibit231.htm
Document

Exhibit 23.1


Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statements (Form S-3 Nos. 333-267822, 333-270132 and 333-277224) of Arcus Biosciences, Inc.,
(2)Registration Statements (Form S-8 Nos. 333-236915, 333-253474 and 333-262929) pertaining to the Arcus Biosciences, Inc. 2018 Equity Incentive Plan, the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, and the Arcus Biosciences, Inc. 2020 Inducement Plan,
(3)Registration Statements (Form S-8 Nos. 333-230074, 333-270114, 333-277219 and 333-285205) pertaining to the Arcus Biosciences, Inc. 2018 Equity Incentive Plan and the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, and
(4)Registration Statement (Form S-8 No. 333-223746) pertaining to the Arcus Biosciences, Inc. Amended and Restated 2015 Stock Plan, the Arcus Biosciences, Inc. 2018 Equity Incentive Plan, and the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan;
of our reports dated February 25, 2026, with respect to the consolidated financial statements of Arcus Biosciences, Inc. and the effectiveness of internal control over financial reporting of Arcus Biosciences, Inc. included in this Annual Report on Form 10-K of Arcus Biosciences, Inc. for the year ended December 31, 2025.

/s/ Ernst & Young LLP

San Mateo, California
February 25, 2026


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer